文献速递妇产影像

疑似子痫前期女性中不同厂商血管生成比值与糖基化纤连蛋白诊断性能的比较

Intermanufacturer assessment of diagnostic performance of angiogenic ratio vs glycosylated fibronectin in women with suspected pre-eclampsia.
PubMed 文献 · Ultrasound Obstet Gynecol · 2024-09-29

前瞻性单中心双盲非干预研究纳入236例疑似子痫前期孕妇,比较三种平台sFlt-1/PlGF比值与GlyFn即时检测的诊断性能。各平台sFlt-1/PlGF比值标准化至等效阈值后排除7天内子痫前期的阴性预测值相似(82.0%–83.3%),GlyFn>263 μg/mL为82.6%;纳入28天内子痫前期的阳性预测值均欠佳(sFlt-1/PlGF比值46.7%–52.3%,GlyFn>263 μg/mL为35.4%)。

要点

  • 各平台sFlt-1/PlGF比值标准化至等效阈值后诊断性能相似。
  • sFlt-1/PlGF比值与GlyFn>263 μg/mL均可用于排除7天内子痫前期,NPV中等。
  • 纳入28天内子痫前期的PPV仍较差。

核心结论

  • 不同厂商sFlt-1/PlGF比值检测标准化至共同阈值后,纳入和排除子痫前期的预测性能相似;sFlt-1/PlGF比值和GlyFn以263 μg/mL为界值均可用于排除评估后7天内的子痫前期,NPV中等;纳入28天内子痫前期的PPV仍较差。

研究设计与样本

  • 前瞻性、单中心、双盲、非干预性研究,纳入2020年1月至2022年3月期间妊娠20周后因高血压就诊的东亚单胎妊娠女性236例,排除就诊时已诊断子痫前期者,子痫前期诊断依据2018年国际妊娠高血压研究学会分类。

诊断标准与关键数值

  • Roche平台sFlt-1/PlGF比值≤38用于预测7天内无子痫前期,各平台高/低分类阈值经Passing-Bablok回归推导为等效于Roche比值38的平台特异性阈值。
  • Roche平台sFlt-1/PlGF比值>38者88例(37.3%),KRYPTOR平台>55者79例(33.5%),iMAGIN 1800平台>40者96例(40.7%)。
  • GlyFn采用263 μg/mL和510 μg/mL两个临床管理阈值,>263 μg/mL者62例(26.3%),>510 μg/mL者4例(1.7%)。
  • 排除7天内子痫前期的NPV:Roche平台83.3%,KRYPTOR平台82.0%,iMAGIN 1800平台82.9%,GlyFn>263 μg/mL为82.6%,GlyFn>510 μg/mL为70.4%。
  • 纳入28天内子痫前期的PPV:Roche平台50.5%,KRYPTOR平台52.3%,iMAGIN 1800平台46.7%,GlyFn>263 μg/mL为35.4%,GlyFn>510 μg/mL为50.0%。

临床应用与阅片要点

  • 作者认为,sFlt-1/PlGF比值和GlyFn以263 μg/mL为界值均可用于排除评估后7天内的子痫前期,NPV中等;纳入28天内子痫前期的PPV仍较差。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To compare the diagnostic performance of different manufacturers' immunoassays for the soluble fms-like tyrosine kinase-1 (sFlt-1)-to-placental growth factor (PlGF) ratio with that of a point-of-care (PoC) test for glycosylated fibronectin (GlyFn) in women with suspected pre-eclampsia (PE).

METHODS: This was a prospective, single-center, double-blinded, non-interventional study of East Asian women with a singleton pregnancy who presented with hypertension with or without clinical features of PE after 20 weeks' gestation between January 2020 and March 2022. Maternal serum samples were collected at the time of presentation, and subsequent management followed the departmental protocol, based on gestational age, severity of hypertension, fetal condition and presence of severe PE features. Women diagnosed with PE at presentation were excluded. PE was diagnosed according to the 2018 International Society for the Study of Hypertension in Pregnancy classification. Levels of sFlt-1 and PlGF were measured using the Cobas e411 (Roche Diagnostics), BRAHMS KRYPTOR (ThermoFisher Scientific) and iMAGIN 1800 (Ningbo Aucheer) platforms. GlyFn levels were measured using the Lumella™ GlyFn PoC test (DiabetOmics Inc.). The predictive performance of each test to rule out PE within 7 days and rule in PE within 28 days from the date of presentation was assessed. Based on the PROGNOSIS study, a sFlt-1/PlGF ratio of ≤ 38 on the Roche platform was used to predict the absence of PE within 7 days. The sFlt-1/PlGF ratio was classified as high or low using platform-specific thresholds equivalent to a Roche sFlt-1/PlGF ratio of 38, which were derived using Passing-Bablok regression. GlyFn was categorized as high or low using two reported clinical management thresholds (263 μg/mL and 510 μg/mL).

RESULTS: Overall, 236 women with suspected PE were included, of whom 70 (29.7%) were diagnosed with PE; 36 (51.4%) and 70 (100%) developed PE within 7 days and 28 days, respectively. Eighty-eight (37.3%) women had a sFlt-1/PlGF ratio of > 38 on the Roche platform, 79 (33.5%) women had a sFlt-1/PlGF ratio of > 55 on the KRYPTOR platform and 96 (40.7%) women had a sFlt-1/PlGF ratio of > 40 on the iMAGIN 1800 platform. Furthermore, 62 (26.3%) and four (1.7%) women had a GlyFn level of > 263 μg/mL and > 510 μg/mL, respectively. The negative predictive value (NPV) of the sFlt-1/PlGF ratio measured on the Roche, KRYPTOR and iMAGIN 1800 platforms to rule out PE within 7 days after presentation was 83.3%, 82.0% and 82.9%, respectively, while that for GlyFn > 263 μg/mL and > 510 μg/mL was 82.6% and 70.4%, respectively. The corresponding positive predictive values (PPV) to rule in PE within 28 days after presentation were 50.5%, 52.3% and 46.7%, respectively, for the sFlt-1/PlGF ratio, and 35.4% and 50.0%, respectively, for GlyFn > 263 μg/mL and > 510 μg/mL.

CONCLUSIONS: The predictive performance of different manufacturers' assays for the sFlt-1/PlGF ratio to rule in and rule out PE were similar once standardized to a common threshold. Our findings suggest that the sFlt-1/PlGF ratio and GlyFn using a cut-off of 263 μg/mL can both be utilized to rule out PE within 7 days after assessment, with a moderate NPV. The PPV for ruling in PE within 28 days remains poor. © 2024 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Wah IYM, Sahota DS, Wong NKL, et al. Intermanufacturer assessment of diagnostic performance of angiogenic ratio vs glycosylated fibronectin in women with suspected pre-eclampsia. Ultrasound Obstet Gynecol. 2024. PMID: 39344277. doi:10.1002/uog.29107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。